{"schema_version":"secwatch.filing_event.v1","accession":"0000950157-22-001253","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.136822+00:00","generated_at":"2026-06-21T12:22:50.112964+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viatris closes $3.335B biosimilars sale to Biocon Biologics; receives $2B cash and 12.9% equity stake","bullets":["Total consideration: $2B cash at close, $1B convertible preferred equity (12.9% stake), plus $335M in future cash payments in 2024.","2022 revenue expected ~$80M lower and adjusted EBITDA ~$20M lower due to transaction; ~$400M in deal-related expenses incurred.","Net proceeds to be used to pay down short-term debt, fund ~$700-750M ophthalmology acquisitions (Q1 2023), and initiate share buybacks in 2023.","Viatris and Biocon Biologics entered a 2-year Transition Services Agreement for business continuity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950157-22-001253","json":"https://secwatch.observer/filing/0000950157-22-001253.json","markdown":"https://secwatch.observer/filing/0000950157-22-001253.md","text":"https://secwatch.observer/filing/0000950157-22-001253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:22:50.112964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc16fa63ecf202fcf79829563d1584338e1ae7f2","claim":"Viatris Inc completed a disposition involving Biocon Biologics Limited for $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in (closed 2022-11-28).","evidence_excerpt":"On November 29, 2022, Viatris Inc., a Delaware corporation (“ Viatris ”), announced that it closed the previously announced transaction with Biocon Biologics Limited, a public limited company incorporated under the India Companies Act, 2013 (“ Biocon Biologics ”), involving the transfer by Viatris of substantially all of its biosimilars portfolio (the “ Biosimilars Business ”) to Biocon Biologics and its subsidiaries (the “ Transaction ”) in exchange for consideration from Biocon Biologics and its subsidiaries of $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in the Transaction Agreement (as defined below), (b) a convertible preferred equity stake in Biocon Biologics initially representing 12.9% of the equity in Biocon Biologics (on a fully diluted basis), which the parties’ valued at $1 billion in the Transaction, (c) $160.0 million in future cash consideration, payable on the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Biocon Biologics Limited"},{"label":"Consideration","value":"$3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in"},{"label":"Closing","value":"2022-11-28"}],"fact_type":"ma_transaction"},{"claim_id":"1c5b2c71496a7f44c2996e8badf6416f77b81e6c","claim":"Viatris Inc amended Amendment No. 1 with Biocon Biologics Limited (effective 2022-11-28).","evidence_excerpt":"On November 28, 2022, prior to the closing of the Transaction, Viatris and Biocon Biologics entered into Amendment No. 1 (\" Amendment No. 1 \") to the Transaction Agreement, dated as of February 27, 2022, between Viatris and Biocon Biologics","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Biocon Biologics Limited"},{"label":"Effective","value":"2022-11-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}